Helga D Manthey

Summary

Affiliation: University of Queensland
Country: Australia

Publications

  1. doi request reprint Complement component 5a (C5a)
    Helga D Manthey
    School of Biomedical Sciences, University of Queensland, Brisbane, Australia
    Int J Biochem Cell Biol 41:2114-7. 2009
  2. doi request reprint Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE-/- mice
    Aya Matsumoto
    School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia
    Int J Cardiol 167:1282-8. 2013
  3. doi request reprint Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice
    Helga D Manthey
    School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia
    FASEB J 25:2447-55. 2011

Collaborators

Detail Information

Publications3

  1. doi request reprint Complement component 5a (C5a)
    Helga D Manthey
    School of Biomedical Sciences, University of Queensland, Brisbane, Australia
    Int J Biochem Cell Biol 41:2114-7. 2009
    ..Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy...
  2. doi request reprint Effects of exercise training and RhoA/ROCK inhibition on plaque in ApoE-/- mice
    Aya Matsumoto
    School of Human Movement Studies, The University of Queensland, Brisbane, Queensland, Australia
    Int J Cardiol 167:1282-8. 2013
    ..The aim of this study was to compare the effects of a RhoA/ROCK inhibitor (fasudil) and exercise in the Apolipoprotein E knockout (ApoE(-/-)) mouse model of atherosclerosis...
  3. doi request reprint Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice
    Helga D Manthey
    School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia
    FASEB J 25:2447-55. 2011
    ..o.) for 25 wk reduced lesion size and lipid content in the plaque by ∼ 40% (P<0.05). Our study provides evidence for a proatherogenic role for C5a and identifies the CD88 antagonist PMX53 as a potential antiatherosclerotic drug...